Lactoferrin: Antiviral activity of lactoferrin

Advances in Experimental Medicine and Biology

Volumn 443, Issue , 1998, Pages 205-213

  Swart, Pieter J ^a   Kuipers, E Mirjam ^a   Smit, Catharina ^a   Van Der Strate, Barry W A ^a   Harmsen, Martin C ^b   Meijer, Dirk K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Department of Immunology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRIN;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS; VIRUS INFECTION; ANIMAL; ARTICLE; CATTLE; CELL LINE; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; FIBROBLAST; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

BOVINAE; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CATTLE; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FIBROBLASTS; HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION;

EID: 0031610282     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9068-9_24     Document Type: Article

References (28)

1. Plummer G: Cytomegaloviruses of man and animals. Prog Med Virol 1973;9:302-340.
2. Weller TH: The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med 1971;285:203-214.
3. Skolnik PR, Kosloff BR, and Hirsch MS: Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988;157:508-514.
4. Davis MG, Kenney SC, Kamine J, Pagano JS, and Huang ES: Immediate-early gene region of human cytomegalovirus trans-activates the promotor of human immunodeficiency virus. Proc Natl Acad Sci USA 1987;84:8642-8646.
5. Drew WL, Mintz L, Miner RC, Sands M, and Kettener B: Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981;143:188-192.
6. Bowden RA: Antivirals for cytomegalovirus. In: Multidisciplinary approach to understanding cytomegalovirus disease. MIchelson S, and Plotkin SA (Eds.). Exerpta Medica, Amsterdam, 1993,pp. 241-249.
7. Azad RF, Driver VB, Tanaka K, Crooke RM, and Anderson KP: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993;37:1945-1954.
8. Bryant LA, and Sinclair JH: Inhibition of human cytomegalovirus major immediate early gene expression by antisense RNA expression vectors. J Gen Virol 1993;74:1965-1967.
9. Snoeck R, Neyts J and De Clercq E: Strategies for the treatment of cytomegalovirus infections. In: Multidisciplinary approach to understanding cytomegalovirus disease. MIchelson S, and Plotkin SA (Eds.). Excerpta Medica, Elsevier Science Publishers B.V. Amsterdam, 1993,pp. 269-278.
10. Haas M, Meijer DKF, Moolenaar F, De Jong PE and De Zeeuw D: Renal drug targeting: optimalisation of renal pharmacotherapeutics. In: International Yearbook of Nephrology 1996. Andreucci VE, and Fine LG (Eds.). Oxford University Press, 1996,pp. 3-11.
11. Mayor U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P, and Schinkel AH: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br J Pharmacol 1996;119:1038-1044.
12. Kuipers ME, Huisman JG, Swart PJ, de Béthune M-P, Pauwels R, De Clercq E, Schuitemaker H, and Meijer DKF: Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J Acq Immun Defic Synd Hum R 1996;11:419-429.
13. Purtell JN, Pesce AJ, Clyne DH, Miller WC, and Pollak VE: Isoelectric point of albumin: Effect on renal handling of albumin. Kidney Int 1979;16:366-376.
14. Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T: Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982;28:219-228.
15. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
16. Pless DP, and Lennarz WJ: Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 1977;74:134-138.
17. Harmsen MC, Swart PJ, de Béthune M-P, Pauwels R, De Clercq E, The TH, and Meijer DKF: Antiviral effects of plasma and milk proteins: lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J Infect Dis 1995;172:380-388.
18. Jansen RW, Schols D, Pauwels R, De Clercq E, and Meijer DKF: Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993;44:1003-1007.
19. Swart PJ, and Meijer DKF: Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994;2:69-70.
20. Hasegawa K, Motsuchi W, Tanaka S, and Dosako S: Inhibition with Lactoferrin of In Vitro Infection with Human Herpes Virus. Jpn J Med Sci Biol 1994;47:73-85.
21. Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, Jollès P: Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984;145:659-676.
22. Day CL, Anderson BF, Tweedie JW, and Baker EN: Structure of the Recombinant N-Terminal Lobe of Human Lactoferrin at 2.0 Å Resolution. J Mol Biol 1993;232:1084-1100.
23. Matthews THJ, Lawrence MK, Nair CDG, and Tyrrell DAJ: Antiviral acitivity in milk of possible clinical importance. Lancet 1976;2:1387-1389.
24. Gold P: Method of treatment of HIV-seropositive individuals with dietary whey proteins. 1994:1-18; PCT/CA93/00107 (Application number);WO 93/20831 (Patent number).
25. Mok J: HIV-1 Infection. Breast Milk and HIV-1 Transmission. Lancet 1993;341:930-931.
26. Newburg DS, Viscidi RP, Ruff A, and Yolken RH: A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res 1992;31:22-28.
27. Lash JA, Coates TD, Lafuze J, Baehner RL, and Boxer LA: Plasma lactoferrin reflects granulocyte activation in vivo. Blood 1983;61:885-888.
28. Boyle MJ, Connors M, Flanigan ME, Geiger SP, Ford H, Baseler M, Adelsberger J, Davey RT, and Lane HC: The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse - A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J Immunol 1995;154:6612-6623.